Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| SMBBIT | Other Identifier | SMBBIT |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
BLUNTING OF HEMODYNAMIC RESPONSE WILL BE OBSERVED IN PATIENTS NEBULISED WITH DEXMEDETOMIDINE AND NORMAL SALINE.
ONE GROUP OF PTS WILL BE NEBULISED WITH DEXMEDETOMIDINE AND OTHER WITH NORMAL SALINE AND WILL BE OBSERVED DURING AND AFTER INTUBATION FOR ATTENUATION OF HEMODYNAMIC RESPONSE FOR LYRANGOSCOPY AND ENDOTRACHEAL INTUBATION
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| nebulised dexmedetomidine | Experimental | participants will receive nebulised dexmedetomidine 1 microgram/kg diluted in 5ml normal saline via nebulised over 5 minutes, administered 30 minutes before induction of anesthesia. standard monitoring of hemodynamic parameters will be done at baseline, 1 minute and 3 minutes post-intubation |
|
| nebulised saline | Placebo Comparator | participants will receive nebulised 5ml normal saline via nebulised over 5 minutes, administered 30 minutes before induction of anesthesia. standard monitoring of hemodynamic parameters will be done at baseline, 1 minute and 3 minutes post-intubation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dexmeditomidine | Drug | dexmeditomidine 1mcg/kg diluted in 5ml 0.9% sodium chloride, administered via nebulizer over 5 minutes, 30 minutes prior to anesthetic induction . |
|
| Measure | Description | Time Frame |
|---|---|---|
| change in mean artirial pressure and heart rate after lyrangoscopy and intubation | hemodynamic stress response measured as change in mean arterial pressure and heart rate from baseline. MAP and HR will be recorded at baseline T0, 1 minute post intubation T1 ans 3 minute post intubation T3. Significant stress response is defined as rise in MAP nad HR more than 10% of baseline at 3 minutes post intubation. | baseline, 1 minute and 3 minute post intubation |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| SMBBIT | Karachi | Sindh | 7500 | Pakistan |
Individual participant data will not be shared publicly to protect participant confidentiality and privacy as per institutional ethics committee guidelines and informed consent obtained from participants. Data may be shared upon reasonable request to the principal investigator, subject to approval by the institutional ethics committee and execution of a data sharing agreement.
Not provided
Not provided
Not provided
Not provided
Not provided
Participants were randomly assigned to one of two parallel groups: Group A received nebulised dexmedetomidine 1 mcg/kg, and Group B received nebulised normal saline 5 ml. Both groups received intervention 30 minutes before induction of anesthesia.
Not provided
Not provided
Participants were blinded to treatment allocation. Treatment was placed in sealed opaque envelopes and selected randomly. The outcome assessor who recorded blood pressure and heart rate was blinded to group allocation to minimize observer bias.
| Normal Saline (0.9% Sodium Chloride) | Drug | normal saline 5 ml administered via nebulizer over 5 minutes, 30 minutes prior to anesthetic induction. |
|
| ID | Term |
|---|---|
| D000077330 | Saline Solution |
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |
Not provided
Not provided